Objectives: To conduct psychometric analyses to condense the Hot Flash-Related Daily Interference Scale (HFRDIS) into a shorter form termed the Hot Flash Interference (HFI) scale; evaluate cut-points for both scales; and establish minimally important differences (MIDs) for both scales.
T he Hot Flash-Related Daily Interference scale (HFRDIS) is a widely used, psychometrically sound, 10-item, self-report questionnaire assessing the impact of hot flashes on a woman's life. 1 The scale was introduced in 2001 to capture a symptom dimension (interference) that had not been previously considered in vasomotor symptom research because there were no assessment tools. 1 The scale was based on similar pain interference 2 and fatigue interference 3 measures. 1 Since publication, the HFRDIS has been translated to 12 languages, cited over 175 times in journal articles and textbooks, and was included as an outcome measure within the National Cancer Institute Physician Data Query Cancer Information Summaries for Supportive and Palliative Care (Coping with Cancer). 4 The HFRDIS is psychometrically strong with demonstrated responsiveness to interventions such as pharmacologic treatments, dietary supplements, and behavioral therapies. [5] [6] [7] [8] [9] Interpretation of HFRDIS scores in research and clinical practice is limited by a lack of investigation in two areas. Cutpoints delineating mild, moderate, and severe interference and a minimally important difference (MID) have never been evaluated. A MID is ''the smallest difference in score in the domain of interest that patients perceived as important, either beneficial or harmful, and that would lead the clinician to consider a change in the patient's management'' (p. 377). 10 In addition, although the scale has only 10 items, a shorter scale could be more useful in busy clinical practices or in research where the HFRDIS is one of many measures to be completed by participants. Anecdotally, in using the scale over the past 15 years, the first author has noticed a pattern to women's responses where a few items are more likely to be rated as zero or no interference, suggesting they may not be important items. Thus, there may be potential to create a shorter scale. According to psychometric theory, short form scales can be developed through psychometric testing and can perform equally well as the longer scales from which they are derived. 11 Gaining expert opinion on the content validity of items, and performing psychometric analyses of women's responses to the scale could help identify the most salient items to retain in a shorter version of the scale. Such analyses have not been reported.
Therefore, given the widespread use, yet limited knowledge, of HFRDIS cut-points and MIDs, and the desire to create a shorter scale, we conducted psychometric analyses to condense the HFRDIS into a shorter Hot Flash Interference (HFI) scale; establish cut-points for both scales; and establish MIDs for both scales.
METHODS

Design
This was an analysis of baseline and postrandomization data from 899 perimenopausal and postmenopausal community-dwelling women who participated in MsFLASH trials 01, 02, and 03. The three MsFLASH studies used standardized methods. 12, 13 Common to all studies was a minimum eligibility criterion of 14 hot flashes per week. All studies were approved by the Institutional Review Boards at clinical sites and the Data Coordinating Center (DCC). Participants provided written informed consent and authorization to use protected health information. [14] [15] [16] [17] [18] MsFLASH 01 was a randomized, placebo-controlled, double-blind trial of escitalopram 10 mg/d or placebo for 8 weeks.
14 If a reduction in vasomotor symptoms (VMS) frequency of at least 50% or a decrease in VMS severity after 4 treatment weeks was not achieved, the dose was increased to 20 mg/d (or matched placebo) without revealing the randomization. Approximately equal numbers of AfricanAmerican and White women were enrolled. Baseline and 8-week postrandomization data were used in this analysis.
MsFLASH 02 was a 3 Â 2 factorial, randomized controlled trial. [15] [16] [17] We randomized eligible participants in a 3:3:4 ratio to 12 weeks of yoga, exercise, or usual activity, and simultaneously randomized in a 1:1 ratio to 1.8 g/d of omega-3 fatty acid or placebo. The omega-3 component of the trial was double-blinded. 15 Baseline and 12-week postrandomization data were used in this analysis.
MsFLASH 03 was a randomized, placebo-controlled, double-blind, 8-week trial of low-dose oral 17-beta-estradiol (E 2 ) 0.5 mg/d, venlafaxine XR (37.5 mg/d the first week, then 75 mg/d), or placebo in a 2:2:3 ratio. 18 Baseline and 8-week postrandomization data were used in this analysis.
Setting and participants
Participants were recruited from July 2009 to October 2012, primarily by mass mailings to age-eligible women using purchased mailing lists and health-plan enrollment files. Common inclusion criteria for all trials included: women aged 40 to 62 years, in the menopause transition (amenorrhea !60 days in the past year), or postmenopausal (!12 months since last menstrual period or bilateral oophorectomy), or had a hysterectomy with one or both ovaries remaining and FSH above 20 mIU/mL and E 2 50 pg/mL or less, and in general good health as determined by medical history, physical examination, and blood tests. Hot flashes had to be rated as bothersome or severe on at least 4 days or nights per week, and the frequency in screening week 3 could not decrease above 50% from the mean weekly levels in screening weeks 1 and 2. Common exclusion criteria were: use of prescription or over-the-counter treatments for hot flashes (past 30 days), use of hormones or hormonal contraceptives (past 2 months), pregnancy or breastfeeding, any current severe or unstable medical conditions, drug or alcohol abuse (past year), history of myocardial infarction, angina or cerebrovascular events, or a major depressive episode (past 3 months).
Procedures
Interested women completed telephone screening and, if eligible, completed a 2-week VMS diary and questionnaire with more detailed screening questions. Those who remained eligible completed a clinic visit for baseline assessment. They continued with the diary and completed a second clinic visit to confirm eligibility (second baseline visit) and complete randomization. To encourage protocol adherence and assess adverse events, telephone calls were made 1 or 2 weeks after randomization, and then again midway through the intervention periods. Follow-up clinic visits were conducted at midpoint and end of study: 4 and 8 weeks postrandomization (MsFLASH 01 and 03), or 6 and 12 weeks postrandomization (MsFLASH 02).
Measures
Baseline demographic characteristics collected from all women included age, race, ethnicity, menopausal status, education, and income. Height and weight were assessed by study staff in clinics for calculating body mass index.
The VMS frequency, severity, and bother were collected in the morning and at bedtime on a paper-based daily diary.
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Ratings of severity were 0 (mild) to 2 (severe), and of bother were 0 (not at all) to 3 (a lot). Ratings were used to calculate daytime, night-time, and total VMS frequency, severity, and bother. Higher scores indicated worse outcomes.
The following measures were completed at a baseline clinic visit prerandomization and again postrandomization ( 21, 22 Items use varying response categories and scores are calculated using a computational algorithm. Global scores greater than 5.0 are indicative of poor sleep quality and high sleep disturbances, and global scores of at least 8 have also been linked to fatigue. 23 Studies have documented one, two, and three-factor structures for the PSQI, with a three-factor model best representing sleep in midlife women with hot flashes. 24 The scale has demonstrated sensitivity to detect changes in sleep during treatment for primary insomnia 25 and sleep problems concurrent with VMS. 5 The 7-item ISI assesses insomnia severity over the past 2 weeks. Participants rate each item on a 0 to 4 point scale (totals range from 0 to 28). Cut-point scores for severity of insomnia are none (0-7), subthreshold (8) (9) (10) (11) (12) (13) (14) , moderate (15) (16) (17) (18) (19) (20) (21) , and severe (22) (23) (24) (25) (26) (27) (28) . 26 The ISI has the following psychometric properties: good internal consistency with Cronbach's alphas at least 0.90 in people with and without insomnia 26 ; concurrent validity with measures of fatigue, quality of life, and mood 26 ; and responsiveness to treatments for primary insomnia 26 and insomnia concurrent with VMS.
27
The GAD-7 is a seven-item screening and severity measure validated for the four most common anxiety disorders in primary care: generalized anxiety, panic, social anxiety, and post-traumatic stress disorder. Responses to each item are for the past 2 weeks, and range from 0 (not at all) to 4 (extremely), with total scores of 0 to 21. Reliability and validity have been established among more than 2,700 general medical outpatients. 28 GAD-7 cut-points of 5, 10, and 15 represent mild, moderate, and severe anxiety symptoms, respectively.
28,29
Statistical analysis
Demographics were compared across the three trials using Pearson's chi-square and Kruskal-Wallis tests as appropriate.
Condensing the scale
Following recommendations that 5 to 10 experts rate items for content validity, 30 we had 7 menopause experts with MD or PhD degrees and actively involved in menopause research and/or menopause clinical practice rate each HFRDIS item as: essential, useful but not essential, or not necessary. Ratings were done based on their own expertise and experience without knowledge of participants' ratings or scores. We then calculated the content validity ratio (CVR) for each item and selected items to retain in the shorter scale based on a CVR cut-point value of at least 0.622. 31 CVRs range from À1 (none of the experts rated the item as essential) to 1 (all of the experts rated the item as essential), with 0 indicating that 50% of the experts rated the item as essential. A CVR of 0.622 corresponded to seven experts and a onesided test of the null hypotheses that 50% or less of the experts would rate the item as essential at an alpha level of 0.05. 31 Any item below this cut-point was removed. We also examined item distributions. Total scores on both the HFRDIS and HFI were calculated as the average of the items. Since the possible response range for each item was 0 to 10, the average total score on both scales had a possible range of 0 to 10.
We conducted several analyses to evaluate the shortened scale. First, we calculated Cronbach's alphas for the full and shortened scales using data from the total cohort and each trial at baseline and postrandomization.
Next, and because the HFI was conceptualized as measuring a single HFI construct, we sought to verify that a onefactor model showed good fit to the original 10-item HFRDIS data. To assess the fit of the unidimensional hot flash interference construct on the data, we performed four confirmatory factor analyses based on unweighted least squares estimation of the model parameters: total sample and the three trial samples. Good fit of the models was defined as a Comparative Fit Index above 0.95 and a Tucker-Lewis Fit Index above 0.95. 32 We also assessed Standardized Root Mean Square Residual, a reverse measure of fit, with a value of 0 indicating perfect fit and values below 0.08 indicating good fit. 32 Third, we correlated the full and shortened scales with one another, diary outcomes, and MENQOL scores at each time point using data from the total cohort. These associations were estimated using the nonparametric Spearman's rank correlation coefficient (Spearman's rho).
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Evaluating cut-points
We used a theoretically driven approach to evaluate cutpoints for the HFRDIS and HFI in relation to other menopausal symptoms. We applied numeric bounds of mild (0-3.9), moderate (4-6.9), and severe (7-10). We then compared VMS diary, sleep, and anxiety scores among the mild, moderate, and severe HFRDIS groups, and among the mild, moderate, and severe HFI groups. For diary ratings, we used Kruskall-Wallis tests. For sleep and anxiety, we used Kendall's tau coefficients.
The numeric bounds were based on the authors' experiences with how 0 to 10-point numeric rating scales are commonly interpreted in clinical practice and the only published study of symptom interference cut-points we could locate. 33 The study also used symptom severity ratings to establish interference cut-points. Our theoretically driven approach is advantageous over a data-driven approach for two reasons. First, it is less dependent on the idiosyncrasies of a particular sample and distribution of data within that sample. Second, it ensures there are common rather than unique numeric bounds across different symptoms or symptom dimensions. Data-driven approaches to establishing severity and interference cut-points have resulted in equivocal findings across samples and across symptoms. [34] [35] [36] [37] Using common cut-points ensures easier translation into practice.
Establishing MIDs
We calculated HFRDIS and HFI MIDs using anchor-based methods. First, we defined the MID as the mean change in these scales from baseline to postrandomization (8 or 12 weeks) for women who reported a 40% to 60% reduction in VMS frequency during a trial. We used this cut-point because a 50% reduction in hot flashes has been suggested as the minimally clinically important difference. 5, 38 We chose AE10% as a reasonable boundary to ensure there was an adequate sample size of women for the MID analyses. Second, we calculated the MID as the mean change in scores for those that reported a 0.5 to 1.5 decrease in MENQOL total score, which is equal to the percent changing one or more response categories within a domain. We also conducted post hoc analyses to calculate the MID as the median change in scores and found similar results (ie, MIDs within 0.25 points of those found in the mean analysis). Results confirmed the Sample size justification and software We evaluated statistical power post hoc using our available sample and our main hypothesis of a one-factor model for the HFRDIS. Power in confirmatory factor analysis using structural equation modeling is still a developing area of inquiry; sample size guidelines are based on expert recommendations in two areas. First, for testing overall fit of a model, experts recommend a minimum sample size of 200, 39 which we exceeded with our overall sample size (N ¼ 899) and each of our subsamples (n ¼ 205, n ¼ 355, n ¼ 339). Second, for accurately estimating model parameters, Jackson 40 recommends using an optimal participant to parameter ratio of 20:1, although ratios as low as 5:1 are considered acceptable. 41 With a 10-item scale modeled as one factor, there are 20 parameters being estimated (eg, 1 factor loading plus one residual/error parameter per item). Thus, the participant to parameter ratio for the HFRDIS in our study was 45:1 for the overall sample, and above 10:1 for each of the subsamples.
All statistical analyses except for the confirmatory factor analysis were performed using STATA 14 for Windows. The Lavaan 42 statistical package in R was used for the confirmatory factor analyses.
RESULTS
Demographics of the 899 participants in the three trials are shown in Table 1 . Most participants were in their middle 50s, White or African-American, educated beyond high school, never smokers, overweight or obese, and postmenopausal. In all trials, median VMS frequency at baseline was more than 6 per day, with moderate severity and bother, and median hot flash interference was around 3.
Condensed scale
Shown in Table 2 are the experts' CVRs and participants' pooled descriptive data by HFRDIS item. Based on the prespecified CVR cut-point value, we eliminated all items except sleep, mood, and concentration in the HFI. Eliminated items were more frequently endorsed by participants as zero or no interference (22%-37.9%) compared with the three retained items (2.2%-18.1%).
Cronbach's alphas are shown in Table 3 . Alphas for the HFRDIS exceeded 0.92 for all time points and samples. Alphas for the HFI exceeded 0.82 for all time points and samples.
The confirmatory factor analyses suggested that a onefactor model of the HFRDIS fit the data well in the pooled sample, and also in each trial sample (see Table 4 ). Because the one-factor model of the HFI was saturated (ie, just identified with three indicators), all indices showed perfect fit in each sample. In addition, all items for both scales had large factor loadings.
Correlations showing good convergent validity of the HFI are shown in Table 5 . The HFI exhibited strong and positive associations with the HFRDIS (rho !0.907, P < 0.001). The pattern of correlations between the HFRDIS and diary and MENQOL was similar in direction, strength, and significance to the HFI and those outcomes. Cut-points Additional associations are shown in Table 6 . Cut-points of mild (0-3.9), moderate (4-6.9), and severe (7-10) on both the HFRDIS and HFI were significantly and positively associated with symptom measures. More hot flash interference reflected worse VMS diary frequency, severity, and bother, and also worse PSQI sleep, insomnia severity, and anxiety. The associations supported the cut-point values for both scales. Table 7 displays MID results for the HFRDIS and HFI. Overall, the average MID for the HFRDIS was 1.66 and for the HFI was 2.34.
MIDs
DISCUSSION
Hot flash-related daily interference is an important patientreported outcome with the HFRDIS measure having been widely used internationally. This is the first report to evaluate a shortened version of the HFRDIS, to evaluate cut-points, and to establish MIDs for both the HFRDIS and condensed HFI. Data from the 10-item HFRDIS showed good fit to a single hot flash interference factor, suggesting that the singlefactor conceptualization of the three-item HFI was reasonable. The HFI had high internal consistency reliability (Cronbach's alphas) and demonstrated strong construct and convergent validity (correlations). In addition, cut-points for mild, moderate, and severe interference on both the HFRDIS and HFI were associated with VMS diary, sleep, and anxiety symptoms. Finally, we identified MIDs for the HFRDIS and HFI, which may be used in future power analyses to determine appropriate sample sizes for clinical trials and in interpreting responsiveness to change and sensitivity to clinical treatments and other intervention effects over time.
We did not find a single item that was adequate for measuring interference, despite this being a possibility at the start of our analyses. We did not make a priori assumptions regarding the number of items to be retained in the shortened version. Our analytic methods also did not preclude this possibility. Sloan et al 43 present an excellent discussion of the relative advantages of single item versus multi-item scales. Single-item scales are easy to administer, reduce response burden, and can be psychometrically sound with ability to demonstrate validity and change over time, including in response to treatment effects. 43 Multi-item scales can be useful for multidimensional latent constructs, can reduce measurement error, can be scored to handle missing item data, and can improve reliability, validity, responsiveness to change over time, and sensitivity to intervention effects. 43 Our three-item HFI has the advantages of a multi-item scale, and because of its very small number of items, also has other advantages similar to single-item scales such as being easy to administer, with minimal response burden, and demonstrated reliability, validity, and responsiveness to intervention effects.
The three retained HFI items received the highest ratings from experts and were the least likely to receive participant ratings of zero or no interference. The links between frequent, severe, or bothersome VMS and sleep problems, 44 ,45 mood problems, [46] [47] [48] [49] and concentration difficulties 50, 51 have all been previously documented, and are consistent with two previously published MsFLASH reports: MsFLASH trial participants' symptom priorities 52 and symptom clusters. 53 
TABLE 4. HFRDIS confirmatory factor analyses fit indices by study population
Combined sample (n ¼ 899) MsFLASH 01 (n ¼ 205) MsFLASH 02 (n ¼ 355) MsFLASH 03 (n ¼ 339
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In MsFLASH 02, a companion study was added and required trial participants to complete a card sort task to indicate which 3 of 12 possible symptoms they would most like to alleviate. 52 The four most highly rated symptoms were VMS, sleep disruption, concentration impairment, and fatigue. Mood was endorsed much less frequently in this analysis possibly because women with mood disturbances were excluded from the trial. Similarly, using pooled data across the MsFLASH trials (n ¼ 899), five classes of symptom clusters were found. 53 The classes were: hot flash interference, sleep problems, and pain; hot flash interference, sleep problems, mood problems, and pain; hot flash interference and sleep problems; hot flash interference and mood problems; and low severity of all symptoms. Problems with concentration were not measured as a MsFLASH outcome for use in the clusters analysis. In general, these studies substantiate the inclusion of sleep, mood, and concentration problems as the symptoms most closely associated with hot flashes or HFI.
Published findings from one study support the exclusion of the ''relationships with others'' item, but not the interference with ''work'' item. 54 In an analysis of data from the Seattle Midlife Women's Health study, multilevel modeling was used to test correlates of symptom interference. Interference with relationships and work were each measured with diary questions over time, and 0 (not at all) to 6 (extremely or a lot) response options. Hot flash severity was measured over time and rated from 0 (not present) to 4 (extreme).
Interference with relationships was not significantly associated with hot flash severity, but was associated with other variables including mood, sleep symptoms, and forgetfulness/ difficulty concentrating. Interference with work was significantly associated with hot flash severity, depressed mood, difficulty getting to sleep, forgetfulness/difficulty concentrating, and other variables. Differences between our study and this published study might have been related to the longitudinal nature of the published study or differences between measurement tools. However, in both our study and this published study, hot flashes, sleep, and difficulty concentrating did cluster together. The values we identified for the MIDs can be compared with another MID for a similarly scored symptom interference scale. Using pooled data from over 2,000 patients with nerve 
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pain from diabetic neuropathy or postherpetic neuralgia, a 1 to 2-point change on a 0 to 10-point sleep interference mean score was found to be an appropriate MID. 55 This MID range for sleep interference is very similar to our MIDs of 1.56 to 2.57 for HFI.
Study findings should be considered in light of some limitations. First, although MsFLASH 01 trial participants were diverse in terms of race/ethnicity, participants of the remaining two trials were less diverse. All participants were American and English speaking. Therefore, whether our findings will hold true if more diverse samples or translated versions of the scale are included remains to be determined. Second, MsFLASH trials excluded women with mood disturbances, which may have affected the results reported here. Third, we acknowledge the data-driven approach to establishing cut-points as an alternative method that might have yielded different results. [33] [34] [35] [36] [37] Fourth, MIDs can vary among different populations 56 and additional studies may yield different findings.
Future research implications are based on study findings and limitations and include the following. It will be important to replicate our findings in other populations and using different translations of the HFRDIS to determine whether the three-item solution and MIDs hold across populations, including those with mood disturbances, and across different instrument translations. Whereas the three retained items for the HFI were those most relevant to this American sample, it is possible that different items or a different number of items might perform best in non-American or non-English speaking populations. It is also possible that MIDs may vary by population or with different translated versions. In addition, a future study could use a data-driven approach to establish severity-based cut-points for HFI. Methods could follow those outlined by Jeon et al. 33 Using data from two studies involving cancer patients assessed at multiple time points, they used 16 different symptom severity ratings to evaluate cut-points for the corresponding 16 different symptom interference ratings. Interference cut-points varied across the 16 symptoms. The most common cut-points (four symptoms, 25%) followed the categories we used (1-3, 4-6, and 7-10), and the second most common cut-points (three symptoms, 19%) used categories of 1, 2 to 4, and 5 to 10. All other symptoms used different combinations of cut-points. We encourage additional analyses by other investigators and clinicians who have used the HFRDIS.
CONCLUSIONS
In conclusion, we successfully created a shorter HFI scale that will be useful in busy clinical practices to effectively monitor HFI and response to treatment over time. Moreover, our findings may help research studies where response burden may be an issue. The scale cut-points and MIDs for the HFRDIS and HFI should prove useful in interpreting the existing, and future research. We urge clinicians and researchers to consider assessing HFI in midlife women as an important patient-reported outcome and to conduct similar psychometric analyses using existing data from more diverse populations and/or with translated versions of the HFRDIS.
